According to a recent LinkedIn post from Neuromod Devices Ltd, the company is present at the 2026 Joint Defense Veterans Audiology Conference at the DoubleTree by Hilton in Orlando, Florida. The post highlights that Neuromod is promoting Lenire, described there as the first and only FDA-approved bimodal neuromodulation device for tinnitus, at Booth 11.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also emphasizes that Lenire is now positioned as a treatment option for an estimated 3.2 million veterans living with tinnitus through the U.S. Department of Veterans Affairs. This suggests Neuromod is targeting the U.S. veterans’ healthcare channel, which could expand its addressable market and support recurring revenue opportunities if clinician adoption and reimbursement levels are favorable.
For investors, the visibility at JDVAC 2026 indicates a focused push into the audiology and otolaryngology communities that serve veterans. If the VA deployment scales, Neuromod could strengthen its competitive position in tinnitus care and build defensible relationships with public healthcare systems, though commercial impact will depend on real-world utilization and long-term clinical outcomes.